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lated into patients experiencing 37% higher average pain intensity, an 8% decrease 
in QoL, and total additional costs of ~$1277 annually. This study provided a concep-
tual framework to model the health-economic impact of dosing variations based on 
actual dosing information in a realistic and intuitive way. This novel concept can also 
be applied to other disease areas to assess pharmaco-economic outcomes.
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OBJECTIVES: Medications, regardless of effectiveness, do not work in patients who 
do not take them. Poor adherence to prescribed medication regimens has been a well-
recognized problem in all of medicine and patients with chronic conditions, such as 
depression, are less likely to follow prescription orders than those with acute condi-
tions. In depression, several studies have reported a medication adherence rate of 
about 72% within the ﬁ rst month of treatment which drops sharply to about 43% 
after 6 months of treatment. Pharmacists may be able to help improve adherence rates, 
yet no single review has examined the impact of pharmacist interventions on adherence 
to antidepressants. The aim of this study was to summarize the literature and deter-
mine whether pharmacist intervention will 1) improve adherence in depression; and 
2) improve patient-reported outcomes (PRO). METHODS: A systematic review of the 
literature was conducted using the PubMed database to retrieve studies examining the 
impact of pharmacist interventions on adherence to antidepressants and on patient-
reported outcomes, from 1990 to 2010. The following MESH terms were used: 
pharmacist intervention, medication intervention, depression, medication adherence, 
health-related quality of life, patient reported outcomes, and antidepressants. a total 
of 25 papers were retrieved with 11 excluded on the basis of abstract or full-text 
review resulting in 14 studies suitable for inclusion. RESULTS: The most common 
intervention strategy that pharmacists utilized was a combination of drug monitoring 
(baseline assessment and treatment follow-up), drug counseling by telephone and 
personal interviews, and patient education (about medication side effects).The results 
of these interventions were positive, improvement varying from 15% to 19%, and 
also, HRQL improved to varying degrees. CONCLUSIONS: The studies support the 
roles of pharmacists in providing interventions to improve medication adherence in 
depression. The results can provide a basis for future studies examining the cost-
effectiveness of pharmacist interventions in depression. 
PODIUM SESSION II: BIOLOGIC AGENT STUDIES AND METHODS
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OBJECTIVES: To analyze the cost-effectiveness, multinomial expected value of perfect 
information (mEVPI), and budget impact of certolizumab pegol (CZP) compared to 
the used ﬁ rst-line subcutaneously administered tumor necrosis factor (TNF) − inhibi-
tors + methotrexate (MTX) and MTX alone in the treatment of moderate-to-severe 
rheumatoid arthritis (RA) in the Finnish setting. METHODS: An Excel-based, proba-
bilistic lifetime Markov cohort model was developed to assess the cost-effectiveness 
and mEVPI. Treatment efﬁ cacy was measured using the ACR-responses (no ACR20, 
ACR20, ACR50, or ACR70) at 3 months. ACR estimated response rates were based 
on adjusted indirect comparison (MTX as the common comparator) of published 
clinical trials. The health state utilities were estimated from the CZP-trials using 
regression models. The inpatient days were linked to patients’ HAQ-scores according 
to published literature. Cost estimates from Finnish sources were used and assessed 
from payer perspective. Cost and health outcomes were discounted with annual 3% 
discount rate. Undiscounted budget impact of CZP was estimated for years 2010–
2013 using Excel model. Equal inpatient costs and treatment efﬁ cacies were assumed 
for all TNF inhibitors. RESULTS: The lifetime costs for CZP + MTX, etanercept + 
MTX, and MTX alone were c179,986, c201,781, and c186,986, respectively. The 
corresponding QALYs (life-years) were 7.041 (15.697), 6.838 (15.646), and 6.336 
(15.547). According to the cost-effectiveness acceptability frontier, CZP + MTX was 
the optimal treatment option with 58% to 73% probability of being cost-effective at 
willingness-to-pay values of c0–30,000 per QALY gained. The respective mEVPI was 
c5058–3701 per patient. Based on clinical responses, CZP + MTX dominated also 
adalimumab + MTX with 100–85% probability of cost-effectiveness (c0–30,000 per 
QALY gained; EVPI c0–218 per patient). The introduction of CZP produced annual 
budgetary net savings of c0.17–0.80 million during 2010–2013 in budget impact 
analysis. CONCLUSIONS: This analysis shows that, on average, CZP + MTX domi-
nated the other subcutaneously injected TNF inhibitors considered or MTX alone in 
the Finish setting. The use of CZP resulted in budgetary net savings.
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OBJECTIVES: To conduct a Discrete Choice Experiment (DCE) to elicit rheumatoid 
arthritis (RA) patients’ preferences regarding treatment with BIOLOGIC AGENTS 
(BA). METHODS: We designed a DCE with RA patients and seven treatment attri-
butes: effectiveness, route of administration, frequency of administration, local and 
systemic adverse effects, severe infections, and out-of-pocket costs. RA patients who 
had never received BA from one private and one public hospital in Buenos Aires were 
included. a multinomial probit regression model (MNP) was used. RESULTS: A total 
of 240 RA participated (mean age 56.2 [SD 13.5], 87% women, median disease dura-
tion 9 years), all receiving conventional DMARDs (84.5% Metotrexate); median 
Clinical Disease Activity Index 7.5, and median HAQ 0.5. All the attributes showed 
to be signiﬁ cant factors affecting choice of treatment. Most attributes levels showed 
coefﬁ cients with the expected signs and were statistically signiﬁcant. Attributes impor-
tance ranking was in the following order: cost, systemic adverse events, frequency of 
administration, efﬁ cacy, route of administration, local adverse events, and serious 
infection (table). Patients had relatively high monthly WTP for treatments that signiﬁ -
cantly reduced the risk of systemic adverse events: mean 331 (95% CI: 212–499) US 
dollars ($) for a reduction from 30% to 10%; of decreasing dose frequency: mean 
$302 (95% CI: 183–461) for going from weekly to monthly administration; increasing 
treatment efﬁ cacy: mean: $386 (95% CI: 285–532) for 40 versus 20 mm reduction in 
patient global assessment VAS), and also for switching from an intravenous to an oral 
therapy: mean $262 (95% CI: 262–555). CONCLUSIONS: Different treatment attri-
butes had a signiﬁ cant and different inﬂ uence in RA patients’ choice of BA. The results 
of the DCE indicated that most respondents would be willing to pay for treatments 
that importantly reduced the risk of systemic adverse effects, dose frequency, with 
increased treatment efﬁ cacy, and with an oral route of administration.
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OBJECTIVES: Studies of orphan drugs are, by nature, confronted with small patient 
populations, meaning that randomized controlled trials (RCTs) will have limited 
statistical power. Enzyme replacement therapy (ERT) is an orphan drug for Pompe 
disease, a metabolic orphan disease, with a prevalence in the The Netherlands of 1 
per 40,000 births. In order to estimate the (cost-)effectiveness of ERT, we developed 
a disease model founded on all available clinical knowledge. METHODS: We devel-
oped a disease model with a strong clinical basis which linked disease-related factors 
with quality-adjusted life-years. The structure of the Wilson-Cleary health outcomes 
model was used as a blueprint. Based on literature and expert opinion, clinically 
relevant aspects of Pompe disease were applied to the distinct entities of the Wilson-
Cleary model. Data from a Dutch cohort study (n = 94, mean follow-up = 2.7 years) 
were used to quantify the relationships between the different entities by means of 
regression analyses. RESULTS: A conceptual model for Pompe disease was developed 
by establishing a clinically plausible pathway from enzyme activity (“biological vari-
ables” in Wilson-Cleary model) via muscle strength and respiratory function 
(“symptom status”), and MCS and PCS from the SF-36 (“functional status”) to the 
ﬁ nal entity of health utility (“quality of life” using EQ-5D and SF-6D). The strengths 
of the relationships between these entities were based on the results of the regression 
analyses. Patient characteristics such as age, gender, and disease duration affected all 
entities in the model. Therapy was assumed to affect only enzyme activity in the model; 
all other health outcomes could only be affected via an impact on enzyme activity. 
CONCLUSION: We have developed a clinically based model to assess the long-term 
cost-effectiveness of ERT in Pompe disease. The approach used here is expected to be 
applicable in the assessment of other orphan drugs.
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OBJECTIVES: Owing to rapid, persistent efﬁ cacy in reducing pain and preventing 
structural damage, tumor necrosis factor-alpha inhibitors (anti-TNFs) has revolution-
ized the treatment of ankylosing spondylitis (AS). However, the high price of anti-
TNFs has limited their use. Recent studies suggest that increased medication costs by 
adopting anti-TNFs may be offset by decreased values of other cost categories. In most 
cost-effectiveness studies on AS treatments, costs were estimated as a whole. Our 
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objectives were to 1) develop a simulation model which can simulate QoL and differ-
ent cost categories from a societal perspective as affected by AS treatments with 
sequential drugs using the ASAS recommendations at group level; 2) parameterize the 
model using Dutch data; and 3) analyze simulated cost-effectiveness of treatment 
strategies with and without anti-TNFs. METHODS: Discrete-event paradigm was 
selected for model development. Pathways in AS treatments were simulated in conjunc-
tion with changes in AS-speciﬁ c measures. Parameterization was realized using original 
data from an observational cohort of AS patients and literature where necessary. 
Frequencies of visits to rheumatologists and hospitals, and having paramedical treat-
ments, informal/formal care, sick leave, and work disability were estimated using logit 
and Poisson regression models. Health utility was estimated using a proportional-odds 
model. Demographic variables were also considered in model selections. Two com-
pared strategies in the simulation were 1) three Cox-1 plus two Cox-2 selective 
nonsteroidal anti-inﬂ ammatory drugs, and 2) same as strategy 1 plus Etanercept and 
Inﬂ iximab. The simulation was run for 1000 patients until death. RESULTS: Simu-
lated values of QALYs and different cost categories were in reasonable ranges. Pro-
ductivity and hospital costs constituted largest shares of the total costs, and were 
signiﬁ cantly lower in strategy 2 (P < 0.05). The incremental cost per QALY gained of 
strategy 2 against strategy 1 was c25,165. CONCLUSIONS: The model is ﬂ exible and 
promising for assessing actual costs-effectiveness of different treatment strategies for 
different societies. 
PODIUM SESSION II: IRT AND RACH MODELING IN QUALITY OF 
LIFE MEASUREMENT
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OBJECTIVES: To evaluate a new standardized disease-speciﬁ c PRO impact item bank, 
the Kidney Disease Impact Scale (KDIS), among adults with chronic kidney disease 
(CKD). METHODS: A 34-item bank of items measuring disease impact, with stan-
dardized content (differing only in disease attribution) and standardized IRT-based 
parameters from previous studies across therapeutic areas, was administered to 516 
CKD patients, along with CKD-speciﬁ c legacy (KDQOL Effects and Burden scales) 
and a generic (SF-12v2) health survey. All measures were administered in a clinic 
setting at three time points (baseline, 1 week, and 3 months) to evaluate: 1) reliability 
(internal consistency and 1-week test–retest); 2) validity in discriminating among CKD 
groups differing in clinically deﬁ ned disease severity (nondialysis stages 3–5, dialysis 
patients, and transplant patients); and 3) responsiveness (better, same, or worse after 
3 months). Real-data CAT simulations were performed, using only the responses to 
items that would have been selected and asked during a real CAT, to estimate KDIS 
scores based on the full bank, and 5-, 10-, and 15-item CATs. RESULTS: As hypoth-
esized, CAT-based score distributions were less skewed and estimates were more 
efﬁ cient (covered a wider range and were as reliable with fewer items), in comparison 
with legacy measures. All KDIS forms (full bank, various lengths of CATs) discrimi-
nated among clinically deﬁ ned groups as well or better than legacy CKD-speciﬁ c 
measures and correlated substantially with generic HRQOL measures. Relative valid-
ity (RV) coefﬁ cients for discriminant validity and responsiveness tests for 1-minute 
(5-item) CAT-based administrations compared favorably with scores based on the 
entire bank (RV = 0.84), KDQOL scores (RV = 0.79 for Burden and 0.50 for Effects), 
and generic measures (RV = 0.00 to 0.59, median = 0.13). CONCLUSIONS: Disease-
speciﬁ c PROs can be improved to be more practical and more valid, in comparison 
with legacy CKD-speciﬁ c and generic PROs. CKD impact measures that perform better 
psychometrically tend to perform better in empirical tests of clinical validity.
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OBJECTIVES: The DLQI is a 10-item generic dermatological HRQoL measure used 
widely with psoriasis patients. The PSORIQoL is a 25-item psoriasis-speciﬁ c measure 
that employs the needs-based model of quality of life (QoL). Both measures have been 
shown to have good psychometric properties using Classical Test Theory. However, 
their scaling properties have not been fully assessed using Item Response Theory (IRT). 
This is the purpose of the study. METHODS: Psoriasis patients, recruited from an 
out-patients clinic, completed the DLQI and PSORIQoL. IRT (Rasch analysis) was 
used to determine each measure’s overall ﬁ t to the Rasch model, individual item ﬁ t, 
targeting of scales to severity of respondents, functioning of response categories, and 
the presence of Differential Item Functioning (DIF) by age or gender. RESULTS: 146 
psoriasis patients were included in the study (male 50%, mean age = 44.2, range = 
17–83 years). DLQI: There was overall misﬁ t to the Rasch model (χ2 = 39.85, df = 
20, P = 0.005). One item misﬁ t the Rasch model and another showed borderline misﬁ t. 
Four of the 10 items had disordered response thresholds indicating that they did not 
work in a logical way. Too few DLQI items covered milder levels of HRQoL (meaning 
that the measure is not sensitive to change in patients with mild disease). DIF by age 
was found in one item and DIF by gender in another. PSORIQoL: Overall, the measure 
ﬁ t the Rasch model (χ2 = 56.45, df = 50, P = 0.247), although one item had a high 
ﬁ t residual suggesting misﬁ t. The response options worked logically and items were 
well distributed across the QoL measurement range. No DIF by age or gender was 
found. CONCLUSIONS: Application of Rasch analysis indicated that there were 
several problems with the scaling properties of the DLQI. In contrast, the PSORIQoL 
ﬁ t the Rasch model and exhibited good measurement properties.
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OBJECTIVES: This study aims to provide sample-free estimates of uniform DIF on a 
newly developed HRQL questionnaire, PROQOL-HIV, based on IRT. Patient char-
acteristics considered here were gender, country of residence, and ethnicity, given the 
high prevalence of HIV in migrant populations. METHODS: We use a two-step 
ordinal logistic regression to test for the signiﬁ cance of person covariates, on two 
constructs extracted from factor analysis: Physical Health and Symptoms (PHS, 14 
items), and Emotional distress and Health Concerns (EDHC, 10 items). a subset of N 
= 505 patients (71% males, median age 43 years) from ﬁ ve countries (Australia, United 
States, France, Brazil, and Thailand) was used. Person parameters were estimated 
using a Graded Response Model. Missing responses (<1%) were imputed using half-
rule. RESULTS: The EDHC dimension was more prone to exhibit item biases com-
pared to PHS items, especially when referring to ethnicity. Country-related effects were 
equally distributed on the two scales. In both cases, however, no DIF effects were 
found for gender. We reached similar conclusions when comparing the results to those 
obtained when using sum or rest scores as conditioning ability levels. Correlations 
between raw scores computed with or without ﬂ agged items were above 0.5. Restrict-
ing analyses to Western countries, however, yielded smaller hits. Altogether, these 
results suggest that DIF effects should be of limited impact when reporting scores for 
these two HRQL dimensions of the PROQOL-HIV questionnaire. Results are dis-
cussed in light of other latent variable models proposed to assess DIF, the MIMIC, 
and logistic mixed effects model. CONCLUSIONS: Using IRT instead of summated 
scale scores allows the incorporation of person covariates and the study of DIF effects 
in a probabilistic framework. The presence of DIF effects on biopsychological con-
structs raises important cross-cultural validity considerations for multi-country multi-
ethnic studies, although assessment of DIF impact needs further investigations.
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OBJECTIVES: No speciﬁ c health-related quality of life (HRQOL) instrument tool is 
available for Huntington’s disease (HD). In the context of a large European study on 
HD burden (Euro-HDB), a speciﬁ c HRQoL tool (HQOLI) was created for patients in 
early and intermediate stages of HD. We describe the development and psychometric 
validation of HQOLI. METHODS: After semistructured interviews with patients, 
caregivers, and HD specialists, we ran a patient focus group. a self-reported question-
naire was then devised in French language. The questionnaire consists of 42 items, 
relating to 11 dimensions: Mobility, Motor Ability, Autonomy 1 and 2, Finance, 
Occupational Activities, Psychology, Feelings of Guilt, Vitality, Socializing, and Body 
Image. Face validity and internal and external validity were examined. RESULTS: 
Among 178 participating patients, 15 did not complete HQOLI. Item response rates 
range from 0.81 to 0.98, excluding the occupational activities domain. As expected, 
there is a ceiling effect on several items, suggesting low sensitivity at advanced HD 
stage. Cronbach’s alphas are greater than 0.76. HQOLI total score is highly correlated 
with generic HR-QOL (SF36 and EQ5D) as well as with the speciﬁ c caregiver HRQoL 
instrument (HDQoL-C). Correlations were −0.73 (P < 0.01) with EQ5D utility, −0.76 
(P < 0.01) with “Physical Functioning,” and −0.74 (P < 0.01) with “Mental Health.” 
Voluntary movement, fall/balance, and dystonia symptoms contribute signiﬁ cantly to 
HQOLI (P = 0.01), but chorea does not (P = 0.21). CONCLUSIONS: These data 
support the validity of the HQOLI in patients with HD. The ceiling effect limits the 
use of HQOLI in late stages but appears necessary to achieve good discrimination at 
early and intermediate stages. Correlations with other instruments suggest good exter-
nal validity. High correlations of several items within dimensions suggest item number 
can be reduced. a new, shorter version of the questionnaire is in development. Assess-
ments of responsiveness to change, test–retest reliability, and cross-cultural validation 
will be performed/are underway. 
